1. Home
  2. EVH vs ALT Comparison

EVH vs ALT Comparison

Compare EVH & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evolent Health Inc

EVH

Evolent Health Inc

HOLD

Current Price

$4.80

Market Cap

469.0M

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$2.61

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVH
ALT
Founded
2011
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
469.0M
421.5M
IPO Year
2015
2005

Fundamental Metrics

Financial Performance
Metric
EVH
ALT
Price
$4.80
$2.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
6
Target Price
$7.93
$17.67
AVG Volume (30 Days)
2.4M
2.6M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
$907,957,000.00
$41,000.00
Revenue This Year
$33.89
N/A
Revenue Next Year
$15.84
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$2.10
$2.56
52 Week High
$11.92
$7.73

Technical Indicators

Market Signals
Indicator
EVH
ALT
Relative Strength Index (RSI) 64.44 36.34
Support Level $3.67 $2.56
Resistance Level $8.30 $4.19
Average True Range (ATR) 0.33 0.12
MACD 0.04 -0.03
Stochastic Oscillator 86.23 9.79

Price Performance

Historical Comparison
EVH
ALT

About EVH Evolent Health Inc

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: